Please login to the form below

Not currently logged in
Email:
Password:

turoctocog alfa

This page shows the latest turoctocog alfa news and features for those working in and with pharma, biotech and healthcare.

CHMP nod for Alexion, GSK drugs, revocation for Lartruvo

CHMP nod for Alexion, GSK drugs, revocation for Lartruvo

Novo Nordisk’s haemophilia A treatment Esperoct (turoctocog alfa pegol), a longer-acting extended half-life factor VIII molecule, which allows patients to inject themselves once every four days, rather than

Latest news

  • US approval for Novo's Factor XIII drug Tretten US approval for Novo's Factor XIII drug Tretten

    In October, Novo secured US approval for NovoEight, a new long-acting Factor VIII for people with haemophilia A (turoctocog alfa), while it also has NN7999, a long-acting recombinant coagulation ... The company suffered a disappointment last year when it

  • EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK

    Novo Nordisk's haemophilia drug. Among the drugs backed by the CHMP, which provides guidance to the European Medicines Agency (EMA), was Novo Nordisk's NovoEight (turoctocog alfa) for use in

More from news
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

What are you doing, Dave?
Artificial Intelligence (AI) is invading all areas of healthcare. Is it our saviour or our nemesis?...
Fake News is Bad for your Health
Ill informed patients make poor health decisions...
Secrets of Pharma Advertising
If the goal of branding is to be different, why do so many Pharma brand ads look the same?...

Infographics